Suggested remit: To appraise the clinical and cost effectiveness of treprostinil sodium within its marketing authorisation for treating chronic thromboembolic pulmonary hypertension.
- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Rationale:
- The NICE Topic Selection Oversight Panel (TSOP), met in August 2022 to carefully consider the suitability of this topic for a Technology Appraisal (TA). The panel concluded it would not be an efficient use of NHS resources to conduct an evaluation. The topic will be formally removed from the NICE work programme.
- ID number:
- 3926
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 November 2022 | Topic selection. . |
| 05 November 2021 - 03 December 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 01 December 2021 | Note added to the project documents |
For further information on how we select topics for development, please see our page about topic prioritisation